Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...

"This is changing the way we practice prostate cancer." ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...